Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Subcutaneous LY3471851 in Healthy Participants
NCT04998487Phase 1Completed
- Sponsor
- Nektar Therapeutics
- Start
- Aug 2021
- Primary completion
- Jul 2022
- Modality
- Biologic, rProtein (Recombinant Protein), Polyethylene glycol conjugate
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rezpegaldesleukin in atopic dermatitis (AD), psoriasis, systemic lupus erythematosus (SLE) and 1 more (2 arms), sponsored by Nektar Therapeutics. Primary endpoints: Maximum Concentration and Area Under the Concentration Versus Time Curve. Started Aug 2021; status: completed.
02
Drugs
rezpegaldesleukin
03
Conditions
atopic dermatitis (AD)psoriasissystemic lupus erythematosus (SLE)alopecia areata
Beyond the preview
Go deeper on NCT04998487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04998487.